Dry Eye Disease is a multifaceted condition which has symptoms such as eye dryness, burning, and stinging sensation in the eyes. As well as clinical diagnosis such as a decreased ability to create tear film. Despite improvements in Contact Lenses (CL) DED still is responsible for a large percentage of CL dropouts due to discomfort. Thus, the purpose of this study is to determine if acoltremon 0.003% can improve the frequency and severity of DED symptoms in CL wearers.

开始日期2026-10-10

申办/合作机构

Southern College of Optometry

NCT07849803

/ Not yet recruiting临床4期IIT

Effect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal Pain

This study is designed to provide clinical data on how acoltremon ophthalmic solution 0.003% affects tear production and ocular symptoms in participants with tear deficiency and concurrent neuropathic corneal pain. Acoltremon is formulated to help increase natural tear production by activating TRPM8 (Transient Receptor Potential Melastatin 8) receptors on cold-sensitive corneal nerves. It is thought that this study treatment may help participants by increasing tear production while potentially reducing neuropathic ocular symptoms, including pain and discomfort.
Participants will be followed for 8 weeks, evaluating the mean change in unanesthetized Schirmer test score between 3 minutes post-drop at Week 8 compared to pre-drop at baseline (Day 1), change in neuropathic symptom intensity as measured by a 0-10 VAS (Visual Analog Scale) from baseline to Week 8, and change in quality of life as assessed by the Ocular Pain Assessment Survey (OPAS) from baseline to Week 8. The study will also evaluate changes in corneal nerve structure, nerve function, corneal sensitivity, ocular surface symptoms, and treatment satisfaction.

开始日期2026-10-01

申办/合作机构

University of South Florida

[+1]

NCT07659626

/ RecruitingN/A

A Randomized, Investigator-masked, Longitudinal Study Evaluating Long-term Changes in Symptoms and Tear Production of Acoltremon Ophthalmic Solution 0.003% Compared to Control in Subjects With Dry Eye Disease

This is a prospective, longitudinal, single-center study designed to evaluate the long-term changes in symptoms and tear production in subjects with dry eye disease. The study is randomized and investigator-masked, with subjects assigned to either the TRYPTYR (Acoltremon ophthalmic solution 0.003%) arm or the control arm (Refresh Classic Preservative-free). The study will be conducted at a single site, with subjects undergoing assessments at baseline and at months 1, 3, 6, 9, and 12.

开始日期2026-08-18

申办/合作机构

The Eye Care Institute

100 项与 Acoltremon 相关的临床结果

登录后查看更多信息

100 项与 Acoltremon 相关的转化医学

登录后查看更多信息

100 项与 Acoltremon 相关的专利（医药）

登录后查看更多信息

项与 Acoltremon 相关的文献（医药）

2026-09-01·EXPERIMENTAL EYE RESEARCH

The neuro-immune-epithelial axis in dry eye: From pathogenic crosstalk to neuromodulatory therapies

Review

作者: Zhang, Jiehao ; Li, Zhijie

Dry eye disease (DED) is commonly described through tear-film instability, tear deficiency, evaporative stress, and ocular surface inflammation. These models remain central to diagnosis and treatment, but they do not fully explain symptom-sign discordance, persistent discomfort after surface-directed therapy, epithelial disease with reduced corneal sensation, or variable treatment responses. In this structured narrative review, we synthesize DED-specific, phenotype-specific, adjacent ocular surface, and translational evidence relevant to a bidirectional neuro-immune-epithelial axis involving corneal sensory nerves, trigeminal-parasympathetic reflexes, epithelial and goblet-cell barrier function, and immune-cell activation. Available sensory evidence indicates that corneal sensory abnormalities in DED are heterogeneous: mechanical esthesiometry more often shows reduced sensitivity, whereas non-contact esthesiometry and pain-enriched cohorts may show hypersensitivity or mixed findings. In vivo confocal microscopy (IVCM) studies suggest concurrent changes in corneal nerve morphology and epithelial immune-cell density, but validated thresholds are not sufficient to define a routine neural DED subtype. Neural dysfunction is therefore considered a phenotype-dependent contributor or amplifier, rather than a universal nerve-first mechanism. Treatment implications are discussed according to evidence strength and directness. Varenicline nasal spray and acoltremon engage reflex or sensory tear pathways where approved; motugivatrep illustrates region-specific TRPV1 translation in Japan; diquafosol and rebamipide are epithelial/mucin-supportive therapies with indirect axis relevance; and cenegermin remains primarily a neurotrophic keratitis therapy with restricted relevance to selected DED phenotypes. Neuropeptide-specific targets, availability-limited device stimulation, and direct nerve-regenerative claims for photobiomodulation remain preliminary. This framework may support mechanism-based stratification and rational adjunctive therapy without replacing established DED classifications.

2026-09-01·Ophthalmology and Therapy

Improvement in Visual-Tasking Daily Living Activities and Work Productivity in Patients with Dry Eye Disease: Integrated Analysis of COMET Studies

Article

作者: Okoro, Tony ; Lappin, Cory J ; Coats, Jade ; Pattar, Guruprasad R ; Lighthizer, Nathan ; Periman, Laura M ; Senchyna, Michelle ; McDonald, Marguerite B ; Nijm, Lisa M

INTRODUCTION:

Dry eye disease (DED) symptoms can impair activities of daily living (ADLs) and work productivity (WP). This post hoc integrated analysis of the phase 2b COMET-1 (NCT04498182) and phase 3 COMET-2 (NCT05285644) and COMET-3 (NCT05360966) studies explored the effectiveness of acoltremon ophthalmic solution 0.003% (ACO [Tryptyr^®]), a recently approved treatment for DED signs and symptoms, on visual-tasking ADLs and WP.

METHODS:

These randomized, double-masked, vehicle (VEH)-controlled studies had similar designs and identical eligibility criteria, enrolling adults aged ≥ 30 years with prespecified DED signs and symptoms. Patients were randomized 1:1 to receive ACO or VEH in both eyes twice daily for 84 (COMET-1) or 90 (COMET-2 and COMET-3) days. The degree that DED symptoms interfered with visual-tasking ADLs and WP was assessed on visual analog scales (VAS; 0-100 mm). ADL/WP and Symptom Assessment iN Dry Eye (SANDE) questionnaires and safety assessments were collected on days 1, 14, 28, and 84/90. Least-squares (LS) mean change from baseline (CFB) and responder analyses were analyzed using analysis of covariance and Cochran-Mantel-Haenszel test, respectively.

RESULTS:

Positive treatment effects in favor of ACO (n = 584) versus VEH (n = 595) were observed for LS mean difference in CFB from days 14 through 84/90 in the ability to use electronic devices (day 14, - 4.4 [P = 0.0016]; day 28, - 5.4 [P = 0.0002]; day 84/90, - 3.4 [P = 0.0378]), a visual-tasking composite score (day 14, - 3.7 [P = 0.0023]; day 28, - 4.2 [P = 0.0012]; day 84/90, - 3.1 [P = 0.0307]), and WP (day 14, - 4.4 [P = 0.0104]; day 28, - 5.4 [P = 0.0028]; day 84/90, - 4.4 [P = 0.0229]). Responder analyses favoring ACO supported the meaningfulness of observed CFB reductions. The only ocular treatment-emergent adverse event with > 1.5% incidence was instillation-site burning or stinging (ACO, 50.2% [97.6% mild]; VEH, 3.2% [100% mild]).

CONCLUSIONS:

These exploratory data suggest that ACO is associated with rapid and sustained improvements in visual-tasking ADLs and WP.

TRIAL REGISTRATION:

COMET-1, NCT04498182; COMET-2, NCT05285644; COMET-3, NCT05360966.

2026-05-01·OPHTHALMOLOGY

Acoltremon 0.003% for Dry Eye Disease: Placing the Phase 3 Results in Perspective

作者: Moshfeghi, Darius M

112

项与 Acoltremon 相关的新闻（医药）

2026-10-18

·眼病唐雷视界

干眼治疗的最新进展，理念、药物、设备……

码字不易，您的关注、点赞和转发就是对我最大的鼓励，谢谢！昨天参加了干眼相关会议，大咖们齐聚前沿，把干眼相关内容进行了深入的讲解和剖析，收获颇丰、受益匪浅，如果有新的药物和设备加持的话，对于临床那种经久不治的干眼患者的治疗效果又会提升一个阶梯，把最新的内容进行了整理归类，以记之。目录：一、干眼流行病学与易感高危人群二、干眼疾病（DED）诊疗前沿进展三、基于 TFOS DEWSⅢ 与《中国干眼临床诊疗专家共识（2024）》四、干眼前沿治疗药物（国内外已上市，含 TFOS DEWSⅢ 推荐新药）五、干眼治疗与诊断设备（循证证据，TFOS DEWSⅢ 推荐）六、总结与展望引言： 2025 年发布的TFOS DEWSⅢ更新了干眼的定义与诊疗逻辑，将干眼从传统 “水液缺乏 / 蒸发过强二元分型” 升级为驱动因素（Drivers）导向的个体化诊疗框架，强调干眼是多因素、有主观症状的疾病，以泪膜 / 眼表稳态丧失为核心，泪膜不稳定、高渗、眼表炎症损伤、神经感觉异常为共同致病要素；症状是诊断必要条件，仅有客观体征不足以诊断干眼，而单纯主观症状也并非心理臆想，重点解释长期困扰临床的症状 - 体征分离现象。结合《中国干眼临床诊疗专家共识（2024）》、《中国干眼患者睑缘管理专家共识（2025）》及近年大量 RCT 与基础转化研究，本文从干眼流行病学与高危人群、临床诊疗痛点难点、现代阶梯化治疗方案、前沿药物与物理治疗设备，为临床精准分型、慢病长期管理提供循证依据，为实际临床提供治疗参考。一、干眼流行病学与易感高危人群 1.1 流行病学特征（TFOS DEWSⅢ 荟萃分析 + 国内人群研究） TFOS DEWSⅢ 整合2017–2024 全球超过 8000 篇文献的荟萃数据：全球成人干眼总体患病率约28.7%，亚洲人群显著高于欧美，亚裔患病率可达 20.1%～34%，种族为独立风险因素；患病率差异高度依赖诊断标准：单纯依靠问卷主观评估会高估，联合泪液渗透压、TBUT、睑板腺成像、MMP-9 等客观指标，患病率显著降低。国内《中国干眼临床诊疗专家共识（2024）》数据：我国干眼患病率21%～52.4%，估算患病人群超 3.6 亿；就诊率仅5.38%，大量患者被误诊为视疲劳、结膜炎，长期未得到规范干预。疾病呈现显著全年龄段、低龄化特征：青少年（18 岁以下）患病率 11.89%～41.6%，主要诱因是视频终端使用；65 岁以上老年人患病率 33.75%。TFOS DEWSⅢ 特别强调：睑板腺功能障碍（MGD）是干眼最主要驱动因素，占临床干眼病例 69%～86%，绝大多数干眼存在多重驱动因素叠加，并非单一类型，蒸发过强组分普遍存在，即使以水液缺乏为主的患者，后期也会合并睑脂异常、眨眼功能异常。健康泪膜三层结构示意图：脂质层（最外层，减少蒸发）、水液层（中间主体）、黏蛋白层（紧贴角膜上皮）；MGD 干眼最外层脂质层变薄、缺损，泪膜快速破裂。 1.2 易感高危人群（循证风险因素） 1、围绝经期、绝经后女性性激素（雌激素、雄激素）下降直接损害睑板腺分泌、泪腺腺泡功能，50 岁以上女性患病风险显著高于同龄男性；妊娠中晚期激素波动同样增加干眼风险。TFOS DEWSⅢ 将性激素异常列为独立驱动因素。 2、高龄人群年龄增长带来睑板腺腺泡萎缩、睑脂熔点升高、角膜神经纤维密度下降、泪腺分泌细胞减少，眼表上皮修复能力减退。 3、视频终端长期使用者（VTD）正常自然眨眼 15～20 次 / 分钟；注视屏幕时眨眼降至 5～7 次 / 分钟，不完全眨眼占比大幅上升，泪膜脂质层快速破裂，是青年、青少年干眼首要诱因；空调、低湿度环境会放大蒸发损伤。不完全眨眼在 DEWSⅢ 中被单独列为眼睑相关核心驱动因素。 4、角膜接触镜佩戴人群软镜长期佩戴破坏泪膜脂质层，诱发低级别持续性眼表炎症，接触镜相关干眼属于典型多重驱动型干眼。 5、内眼及屈光手术后患者全飞秒、准分子激光角膜屈光手术、白内障手术会损伤角膜三叉神经末梢，术后神经源性干眼可持续数月至数年；青光眼滤过手术、睑缘手术亦可加重眼表稳态破坏。DEWSⅢ 将医源性干眼作为独立章节重点阐述，医源性干眼是不争的事实，但临床解释要讲求艺术，诊断也要谨慎，否则，医方很容易被推挤到被动的位置。 6、自身免疫性疾病患者干燥综合征、类风湿关节炎、系统性红斑狼疮，以水液缺乏型干眼为主，常合并重度眼表上皮损伤，属于难治干眼亚组。 7、长期服用影响泪液分泌药物人群抗组胺药、部分抗抑郁药、抗胆碱类药物、降压药、口服维 A 酸类药物，抑制泪腺分泌、改变黏液分泌。 8、睑缘疾病、蠕形螨睑缘炎患者蠕形螨定植破坏睑板腺开口、诱发睑缘慢性炎症，是 MGD 和难治蒸发型干眼关键诱因；《中国睑缘管理专家共识（2025）》推荐所有干眼患者均需要评估睑缘状态。 9、神经心理共病人群慢性焦虑、抑郁、躯体化障碍。TFOS DEWSⅢ 明确角膜神经敏化、神经痛与情绪障碍形成双向恶性循环，患者主诉异物感、烧灼感强烈，但客观检查体征轻微，属于神经感觉异常驱动型干眼，是临床最容易漏诊的亚型。二、干眼诊疗痛点与难点（TFOS DEWSⅢ 重点阐述） DEWSⅢ 最大理念革新：不再简单依靠严重程度分级，优先识别驱动因素；同时正视症状与体征分离这一核心临床难题。 2.1 症状与体征分离，诊断体系存在短板部分患者主观症状（干涩、烧灼、异物感、畏光、视物波动）很重，但 Schirmer、TBUT、角膜染色等客观检查接近正常，属于神经感觉异常驱动干眼；另一部分患者睑板腺大面积萎缩、泪液高渗、MMP-9 阳性，但几乎无明显不适。传统诊断流程仅依靠 Schirmer 试验、泪膜破裂时间，无法识别神经源性干眼。泪液渗透压、MMP-9 快速检测、睑板腺红外成像、角膜共聚焦显微镜（CCM）评估角膜神经纤维密度等检查，在国内基层眼科普及不足，难以完成驱动因素识别，容易将多驱动干眼简单诊断为普通 “缺水干眼”，直接造成治疗方案错配。睑板腺红外成像对比：左图为健康眼睑，睑板腺腺体形态连续、饱满；右图 MGD 患者可见腺体扭曲、缩短、大片缺失（腺体萎缩）。 2.2 发病机制是多重驱动叠加的恶性循环，传统治疗多为对症 TFOS DEWSⅢ 病理机制框架：泪液高渗、脂质层缺损、不完全眨眼、睑缘炎症、角膜神经损伤、免疫炎症激活，多个驱动因素互相促进，形成闭环损伤。普通人工泪液仅短暂补水，不干预炎症、神经损伤、睑板腺阻塞；含防腐剂人工泪液长期使用持续损伤眼表上皮屏障，加重干眼。糖皮质激素抗炎效果强，但长期使用存在眼压升高、后囊下白内障风险，仅适合短期冲击；传统环孢素混悬液起效慢，部分患者眼表刺激明显，依从性受限。临床常只关注 “补水”，忽略睑缘、眨眼模式、角膜神经、全身共病等关键驱动因素。 2.3 慢性疾病，长期慢病管理依从性差干眼属于慢性疾病，无法一次性根治，需要长期个体化慢病管理，这一点与高血压、糖尿病管理理念相似，也是患者最难以接受的现实： 1、症状稍有缓解即自行停药，眼表慢性炎症反复，睑板腺进行性萎缩，逐步发展为难治性干眼； 2、居家基础治疗（热敷、睑缘清洁）执行难度高：热敷温度不足无法融化睑脂，温度过高灼伤睑缘；很多患者仅做热敷，不做睑缘清洁，蠕形螨、睑缘炎症持续存在； 3、门诊设备治疗（IPL、热脉动）费用较高，需要多次复诊，时间与经济成本高； 4、神经感觉异常型干眼，疼痛感知与焦虑互相强化，单纯眼表局部药物、物理治疗效果有限，需要跨学科（疼痛科、心理科）联合干预，常规眼科诊疗体系难以覆盖。 2.4 重度难治干眼治疗手段有限，生物制剂标准化供给不足重度干燥综合征相关干眼、持续性角膜上皮缺损，常规药物和物理治疗效果有限。自体血清、富血小板血浆（PRP）滴眼液可促进上皮修复、抑制炎症，但需要自体采血、制备、冷链储存，标准化量产困难，国内供应受限，难以大规模常规使用。泪点栓塞同样存在局限性：部分患者出现明显异物感、栓子移位、继发感染；对于存在持续眼表高渗炎症的患者，单纯栓塞泪点，无法逆转炎症损伤。 2.5 角膜神经病变识别不足 TFOS DEWSⅢ 专门强调角膜神经功能异常是独立驱动因素，可单独存在，也可叠加在水液缺乏或蒸发型干眼之上。这类患者以烧灼痛、刺痛、畏光为主，常规干眼检查指标接近正常，极易被当成普通干眼反复治疗，常规补水、睑板腺疏通疗效差，需要神经保护、神经调控类方案，国内临床对该亚型识别率偏低。三、干眼整体治疗策略（TFOS DEWSⅢ 驱动导向阶梯方案 + 《中国干眼共识 2024》） TFOS DEWSⅢ 推荐基于驱动因素的个体化阶梯管理，优先去除可纠正诱因，阻断核心致病环路，重建泪膜与眼表稳态，而不是单纯按轻中重度给药。国内共识与之保持一致，阶梯框架如下：第 1 级（基础干预，全部干眼通用）：行为干预（20-20-20法则、纠正不完全眨眼训练）、环境湿度管理、睑缘清洁、除螨治疗、无防腐剂人工泪液 / 脂质型人工泪液；停用诱发干眼的全身及局部药物。第 2 级（针对核心驱动因素）：抗炎免疫调节药物、靶向脂质 /黏蛋白滴眼液；MGD 患者联合睑板腺物理治疗（热脉动、IPL、眼睑射频）。第 3 级（中重度、难治干眼）：泪点栓塞、鼻内三叉神经刺激、PRP / 自体血清滴眼液；针对神经异常的神经保护与神经调控治疗；营养补充（Omega-3）。第 4 级（极重度终末期干眼）：羊膜移植、唇腺移植、巩膜镜等手术 / 特殊光学干预。 TFOS DEWSⅢ 干眼阶梯诊疗流程：先评估驱动因素，由基础干预逐级升级，动态评估，按需降阶维持。前沿研究方向（TFOS DEWSⅢ）：眼表长效黏膜黏附给药系统、ROS 抗氧化治疗、眼表干细胞修复、TRPM8 受体靶向治疗、无创眼磁神经刺激、缓释药物泪点植入物，多数处于临床前或早期临床阶段，尚未商业化。四、干眼前沿治疗药物（国内外已上市，含 TFOS DEWSⅢ 推荐新药） 4.1 靶向脂质修复类（蒸发型/ MGD 核心用药）全氟己基辛烷滴眼液（F6H8），TFOS DEWSⅢ 重点推荐，国内已获批上市。无水制剂，不含防腐剂、无表面活性剂，是专门针对 MGD 相关蒸发过强干眼的局部药物。Ⅲ 期 RCT 证实极低表面张力，可快速铺展眼表，修复泪膜脂质层、降低泪液蒸发率，改善睑脂流动性，延长 TBUT，降低 OSDI 评分；区别于传统人工泪液单纯补水，直接修复脂质层，适合以睑板腺堵塞、脂质层缺损为主要驱动的干眼。 4.2 免疫抗炎类（DEWSⅢ 核心抗炎方案） 1、0.05% 环孢素滴眼液（Ⅱ）国内原创药物，临床证据被 TFOS DEWSⅢ 收录，推荐用于慢性炎症型干眼，抑制 T 细胞介导的眼表免疫炎症，促进泪腺分泌；长期维持治疗，安全性良好。新一代无水环孢素滴眼液（Ⅳ），眼表滞留时间更长，刺激性显著下降，耐受性改善，国内新获批，适合水液缺乏合并慢性炎症干眼。 2、利非司特（Lifitegrast）滴眼液 LFA-1 拮抗剂，阻断 T 细胞黏附活化，同时改善干眼体征与主观症状，TFOS DEWSⅢ 纳入中重度干眼抗炎方案；单剂量无防腐剂，一日两次；起效快，部分患者 2 周即可改善症状，适合中重度炎症驱动干眼。 3、短效糖皮质激素（地氟泼尼酯等）：仅用于急性炎症爆发的短疗程冲击治疗，不可长期维持，必须监测眼压， DEWSⅢ 明确激素为桥接治疗，后续过渡到免疫调节剂长期维持。 4.3 促泪分泌与神经调节药物伐尼克兰鼻喷雾剂：鼻腔给药，激活三叉神经反射通路，反射性刺激泪腺分泌，不直接滴入眼表，规避眼部局部刺激。ONSET 系列 Ⅲ 期临床证实 4 周显著提升 Schirmer 试验数值，TFOS DEWSⅢ 作为神经调控促分泌方案推荐，适合以水液缺乏为主要驱动的干眼。 Acoltremon（TRYPTYR，0.003% 滴眼液），靶向角膜 TRPM8 冷敏受体，FDA 获批，DEWSⅢ 收录；激活TRPM8 受体，抑制眼表痛觉信号、反射促进泪液分泌，快速缓解烧灼感，针对神经感觉异常驱动干眼；国内尚在临床开发阶段。 4.4 黏蛋白保护与辅助药物地夸磷索钠滴眼液：促进结膜上皮分泌黏蛋白，改善泪膜黏蛋白层，TFOS DEWSⅢ 推荐用于黏蛋白缺乏、泪膜稳定性差的干眼。 4.5 生物制剂（重度难治干眼）自体血清滴眼液、富血小板血浆 PRP 滴眼液：富含 EGF、TGF-β 等多种生长因子，修复角膜上皮、抑制眼表炎症，用于持续性角膜上皮缺损、重度干燥综合征干眼。局限：自体取材、制备复杂，无法标准化量产。间充质干细胞（MSC）眼表制剂处于临床前 / 早期临床研究，DEWSⅢ 将其列为未来极具潜力方向，尚未商业化上市。在研新药方向：MMP-9 抑制剂、眼表抗氧化酶制剂、可降解泪点药物缓释植入物，数月持续释放抗炎药物，减少滴眼频次，解决患者依从性难题。五、干眼治疗与诊断设备（循证证据，TFOS DEWSⅢ 推荐） 5.1 睑板腺物理治疗设备（MGD一线设备治疗） 1、热脉动设备（LipiFlow、iLux、TearCare）可控眼睑恒温加热 + 同步脉冲机械挤压，液化淤积睑脂，直接疏通睑板腺，优于单纯居家热敷。多项 RCT 和网状 Meta 分析证实，单次 LipiFlow 治疗可稳定改善 TBUT、睑板腺评分、OSDI 达 6～12 个月；TFOS DEWSⅢ 推荐用于中重度 MGD。 LipiFlow 热脉动治疗装置示意图：一次性眼睑接触眼罩，恒温加热 + 脉冲压力，同步软化睑脂并排出堵塞分泌物。 2、强脉冲光 IPL（OptiLight） DEWSⅢ 推荐 MGD、睑缘炎合并干眼的重要设备。作用机制：封闭睑缘异常毛细血管，减少炎症因子输送；光热软化睑脂；杀灭睑缘蠕形螨；光生物调节改善睑板腺细胞代谢。Meta 分析显示 IPL 联合睑板腺疏通，疗效显著优于单纯睑板腺挤压；常规疗程 3～4 次，间隔 3～4 周。禁忌：深色皮肤、近期日晒、光敏疾病。眼睑射频 RF，可单独使用或联合 IPL，DEWSⅢ 纳入，RCT 证实联合治疗对重度 MGD 优于单用 IPL。 5.2 神经刺激类设备（神经驱动型干眼前沿无创疗法） 1、鼻内神经刺激装置与伐尼克兰鼻喷机制同源，物理刺激鼻腔三叉神经末梢，反射性促进泪液分泌，可作为药物替代或联合方案，TFOS DEWSⅢ 将其列为神经调控治疗方案。 2、眼局部重复磁刺激RMS（VIVEYE）无创电磁刺激角膜三叉神经，早期临床研究显示稳定泪膜、减轻角膜神经源性疼痛，不影响眼压视力，用于神经感觉异常驱动干眼；尚处于临床验证阶段。 5.3 精准诊断设备 TFOS DEWSⅢ 强调，干眼诊断不能仅依靠问卷与基础泪液检查，需要配套客观检测识别不同驱动因素：睑板腺红外成像仪、泪膜干涉仪、泪液渗透压检测、床旁 MMP-9 快速检测（InflammaDry）、角膜共聚焦显微镜（CCM，评估角膜神经纤维密度、上皮炎症）。国内《睑缘管理共识 2025》建议干眼首诊均需完成睑缘照相与睑板腺红外成像，识别 MGD 驱动因素。 5.4 微创与特殊光学干预泪点栓塞（可吸收胶原塞、永久性硅胶塞）：保留自身泪液，适合以水液缺乏为主要驱动的中重度干眼，DEWSⅢ 推荐，但强调栓塞前必须控制眼表急性炎症；巩膜镜 / 迷你巩膜镜用于重度眼表疾病，保护角膜上皮；终末期极重度干眼可选择羊膜移植、唇腺移植手术。六、总结与展望 TFOS DEWSⅢ 带来干眼诊疗范式的转变：从 “二元分型、按轻重分级治疗” 转向 “识别多重驱动因素、个体化精准干预”，并确立了症状是干眼诊断必要条件、神经感觉异常为独立驱动因素的核心认知，很好解释了临床长期存在的症状体征分离难题。结合《中国干眼临床诊疗专家共识（2024）》、《中国干眼患者睑缘管理专家共识（2025）》，当前国内临床工作的核心短板在于基层难以完成驱动因素的识别，很多干眼仍停留在 “单纯人工泪液补水” 的旧模式。近年干眼领域的突破性进展集中于：靶向脂质层新药、新一代无水抗炎滴眼液、IPL / 热脉动睑板腺物理治疗、三叉神经通路神经调控方案。未来研究重点聚焦长效眼表靶向给药、抗氧化、干细胞眼表修复、神经调控疗法。现代干眼管理已经从单纯对症滴眼，升级为病因驱动、阶梯干预、长期慢病管理。临床诊疗应当全面评估多重驱动因素，重点识别 MGD、不完全眨眼、角膜神经异常、全身 / 心理共病，采用药物联合物理设备的个体化方案，同步加强患者宣教，改善长期依从性，减少干眼反复发作，延缓睑板腺与角膜神经不可逆损伤。个人体会：一言以蔽之，干眼的发病机制非常复杂，治疗简单也复杂，否则，也不会有这么多的标准、共识、指南，更新也不会这么频繁，药物也不会这么层出不穷、设备也不会这样升级换代……，特别治疗理念、药物的发展也很迅猛，有的新药已经上市，设备也有很多医院进行了更进/新，不过在基层一时半会还很难…… 因为，大咖是这样说的：参考文献 1.TFOS DEWS III Management and Therapy Report, 2025 2.亚洲干眼协会中国分会等。中国干眼临床诊疗专家共识（ 2024）[J]. 中华眼科杂志，2024,60 (12) 3.中国民族卫生协会干眼研究型学组。中国干眼患者睑缘管理专家共识（2025） 4.PubMed荟萃分析：IPL、LipiFlow 治疗 MGD 网状 Meta 分析 5.ONSET-2 伐尼克兰鼻喷雾剂 Ⅲ 期临床试验 6.国内眼表领域综述：干眼靶向药物研究进展，中华眼视光学与视觉科学杂志关注我可获取全文欢迎留下您的观点，让我们大家共享清晰视界！

临床研究

2026-10-05

·alcon.com

Alcon Highlights Its Comprehensive Innovation Portfolio at AAO 2026

FORT WORTH, October 5, 2026 — Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will highlight its innovation portfolio at the 2026 American Academy of Ophthalmology (AAO) annual meeting, October 10-12 in New Orleans. Attendees visiting Alcon at Booth #1519 can explore hands-on demonstrations spanning cataract, retina, glaucoma and dry eye disease. Featured innovations include the UNITY® platform, highlighted by the new UNITY® M ophthalmic microscope, along with Clareon® PanOptix® Pro, Clareon® TruPlus® IOLs, Valeda™ Photobiomodulation (PBM) and Voyager™ DSLT. "At AAO 2026, Alcon will demonstrate how innovation is redefining what's possible in eye care," said Sergio Duplan, President of the Americas at Alcon. "Attendees will experience firsthand how our portfolio is helping shape the future of eye care through technologies and clinical solutions that support eye care professionals every day." UNITY Booth Demonstrations Provide a Firsthand Look at Alcon's Surgical Platform The UNITY platform will anchor Alcon's AAO presence. Attendees can participate in private demonstrations of both configurations: the UNITY VCS combined console and the UNITY CS standalone cataract system. The recently launched UNITY® M microscope, a premium surgical microscope that delivers precise control for ophthalmic surgeons, will also be featured. Together, these experiences provide a firsthand look at how connected surgical technologies support visualization, workflow efficiency and surgical performance. Alcon experts will be available for one-on-one discussions and product demonstrations throughout the meeting. Recent Innovations Demonstrate Alcon's Broad Eye Care Portfolio Alcon's booth will also feature demonstrations highlighting several of the company's newest innovations. In cataract surgery, attendees can learn more about Clareon PanOptix Pro, the latest evolution of the world's leading trifocal family, as well as Clareon TruPlus IOLs, Alcon's next-generation monofocal and toric IOL platform designed to build on the performance of the Clareon family. In retina, attendees can explore Valeda PBM, the first and only FDA-authorized treatment for patients with early and intermediate dry age-related macular degeneration (AMD), through dedicated technology demonstrations.1 In glaucoma, Alcon will showcase Voyager DSLT, an innovative first-line glaucoma treatment option powered by automated SureTrac eye-tracking technology, which precisely delivers laser pulses through the limbus to the trabecular meshwork.2 In addition to its surgical portfolio, Alcon will highlight TRYPTYR® (acoltremon ophthalmic solution) 0.003%, a prescription treatment option for the millions of patients affected by dry eye disease (DED). As the first neuromodulator eye drop that can rapidly increase natural tear production as early as day one, TRYPTYR represents a novel approach to DED management.3-7 Attendees can learn more about this innovation, including its first-in-class mechanism of action, by visiting Alcon at booth #1519. For more information about Alcon's presence at AAO 2026, including demonstrations, presentations and featured innovations, visit www.MyAlconatAAO.com. Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com. Connect with us on Facebook and LinkedIn. About TRYPTYR® (acoltremon ophthalmic solution) 0.003% INDICATIONS AND USAGE TRYPTYR® (acoltremon ophthalmic solution) 0.003% is indicated for the treatment of the signs and symptoms of dry eye disease (DED). IMPORTANT SAFETY INFORMATION Warnings and Precautions Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces. Use with Contact Lenses: TRYPTYR should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of TRYPTYR. Adverse Reactions In clinical trials, the most common adverse reaction was instillation site pain (50%). Please click here for the TRYPTYR Full Prescribing Information. About Valeda® PBM The Valeda Light Delivery System improves visual acuity in patients with best-corrected visual acuity of 20/32 through 20/70 and who have dry age-related macular degeneration (AMD) characterized by: 1. The presence of at least 3 medium drusen (> 63 μm and ≤ 125 μm in diameter), or large drusen (> 125 μm in diameter), or non-central geographic atrophy, and 2. The absence of neovascular maculopathy or central-involving geographic atrophy. Do not treat patients with Valeda if they have any known photosensitivity to yellow light, red light, or near-infrared radiation (NIR), have a history of light-activated central nervous system disorders (e.g., epilepsy, migraine), or within 30 days of using photosensitizing agents. Treatment benefit may not persist significantly after treatment is stopped. No significant data on the safety and effectiveness for more frequent or extended treatments beyond described in operator’s manual. About UNITY® VCS and CS The UNITY® VCS (Vitreoretinal Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e., phacoemulsification and removal of cataracts) and posterior segment (i.e., vitreoretinal) ophthalmic surgery. The UNITY® CS (Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e., phacoemulsification and removal of cataracts) ophthalmic surgery. Refer to the Directions for Use for the accessories/consumables and User Manual for a complete listing of indications, warnings, cautions and notes. About UNITY® M UNITY® M is the latest ophthalmic microscope available by Alcon. As with all ophthalmic microscopes, exposure during aphakia should be limited to reduce the risk of damage. During aphakia and at maximum illumination intensity, limit exposure to red reflex light to no more than 9.6 minutes. About Clareon® PanOptix® Pro The Clareon PanOptix Pro Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the center of the Clareon PanOptix Pro Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide. Potential Side Effects: Due to the design of multifocal IOLs, there are some side effects that can be associated with the Clareon PanOptix Pro Trifocal IOL models. These may be worse than with a monofocal IOL, including visual disturbances such as glare, rings around lights, starbursts (rays around light sources), and reduced contrast sensitivity (decreased ability to distinguish objects from their background, especially in dim lighting). These side effects may make it more difficult to see while driving at night or completing tasks in low lighting conditions such as at night or in fog or in a dimly lit room after surgery, as compared to before surgery. Kevin Nicoletti + 1 817 913 3461 (Fort Worth) kevin.nicoletti@alcon.com Daniel Cravens + 1 817 615 2789 (Fort Worth) investor.relations@alcon.com

2026-09-03

·网易号

智通港股早知道富时中国50指数调整纳入澜起科技(06809)等美联储褐皮书释放复杂信号

【今日头条】富时中国50指数调整：纳入华虹宏力(01347)、澜起科技(06809)智通财经获悉，9月2日，富时罗素公布对富时中国指数系列的季度审核变更。调整结果将于9月18日盘后生效。富时中国50指数纳入华虹宏力(01347)、澜起科技(06809)等港股。此外，富时中国50指数还公布了新一季的备选股名单，分别为中煤能源(01898)、中信建投证券(06066)、蓝思科技(06613)、药明生物(02269)、兖矿能源(01171)等港股。【大势展望】美股指数悉数收涨 “科技七巨头”涨跌分化隔夜美股截至收盘，道琼斯工业平均指数比前一交易日上涨295.07点，收于53061.95点，涨幅为0.56%；标准普尔500种股票指数上涨35.13点，收于7666.6点，涨幅为0.46%；纳斯达克综合指数上涨118.06点，收于26217.83点，涨幅为0.45%。“科技七巨头”涨跌分化，英伟达涨3.21%，Meta涨2.47%，因财报超预期，戴尔科技涨超15%，GitLab涨近10%。AI应用软件股下挫，MongoDB跌超13%，Datadog跌超6%。纳斯达克中国金龙指数基本持平，报6051.33点，微跌0.05%。恒生指数ADR上涨，按比例计算，收报25508.02点，较香港收市升196.81点或0.78%。纽约商品交易所WTI原油期货当月连续合约上涨0.41美元，收于每桶90.63美元，涨幅为0.45%。COMEX黄金期货当月连续合约上涨37.90美元，涨幅0.86%，报4434.3美元/盎司。【热点前瞻】美联储褐皮书释放复杂信号：通胀难降、消费分化 AI投资仍火热北京时间周四凌晨，美联储发布的8月经济形势报告《褐皮书》显示，尽管美国经济仍在温和扩张，但增长越来越依赖AI数据中心等少数项目，同时通胀压力依然顽固，居民端的压力正在逐步累积，消费“K型分化”愈发显著。恒指公司：将希音-W(00625)纳入恒生综合指数 9月15日起生效智通财经获悉，9月2日，恒指公司发文称，希音国际控股有限公司-W(00625)符合恒生综合指数的快速纳入规则要求，将于2026年9月14日(星期一)收市后被纳入以下恒生综合指数及其分类指数，并于2026年9月15日(星期二)起生效。欧康维视生物-B(01477)：OT-211 III期临床试验完成患者入组OT-211(TRYPTYR®阿考曲孟滴眼液)为一种0.003%浓度滴眼液配方，亦为首款获美国食品药品监督管理局(FDA)批准用于治疗乾眼症(DED)的TRPM8激动剂。2026年3月，OT-211于中国的III期临床试验完成首例患者入组，标志着 OT-211在中国的临床开发取得重要里程碑进展，并体现了集团致力于为DED患者推进创新疗法。康诺亚-B(02162)就司普奇拜单抗注射液东南亚和中亚等18个国家和地区上市注册和商业化达成许可协议根据协议，康诺亚将获得首付款以及不同国家上市申请获批的里程碑付款及商业化里程碑付款，并有权利收取基于许可区域产品净销售额计算高达高双位数率的特许权使用费。本次合作是康诺亚创新生物药国际化战略的重要里程碑，将借助合作方在东南亚及中亚等地区独特的商业网络和注册经验，加快司普奇拜单抗在上述区域的上市及商业化进程，进一步提升本公司创新产品的全球可及性，惠及更多患者。京东健康(06618)与立康生命科技签署战略合作协议9月2日，京东健康(06618)与立康生命科技达成战略合作。双方将围绕个性化mRNA肿瘤疫苗等肿瘤精准免疫治疗创新方向，重点在患者服务、就医协同、临床研究受试者招募及高端健康管理服务等方面展开合作；京东健康作为新特药全网首发第一站，将提供肿瘤疫苗新品首发上市支持，共同推动前沿技术、医疗服务与患者需求实现更加高效、规范的衔接。目前，LK101是国内首款获得药物临床试验许可的个性化mRNA肿瘤疫苗，并于2025年获得美国FDA临床试验许可，现已进入Ⅱ期临床研究阶段。宏华集团(00196)附属与中东客户签署6亿元的钻机销售协议将提供数套大型钻机设备根据销售协议，四川宏华将向该客户提供数套大型钻机设备。该客户为中东本土领先的钻井承包商及油田综合服务商，主要从事区域陆上钻井服务。科笛-B(02487)：CU-20101(注射用A型肉毒毒素)生物制品上市许可申请获得国家药监局受理CU-20101在生产工艺过程中将不使用动物源性材料和人血白蛋白，从而消除传染性海绵状脑病(TSE)感染和相关过敏反应风险，预计将具有良好的安全性优势。 CU-20101将进一步丰富集团的皮肤产品矩阵，并有利于与集团现有产品形成协同效应。面向皮肤治疗市场广泛的需求，多元化产品的布局将有望为集团取得更大的市场份额。【个股点晴】腾讯(00700)：WorkBuddy开放平台正式上线9月2日，腾讯(00700)WorkBuddy开放平台正式上线，全面开放WorkBuddy的能力生态，与万千用户共建持续进化的AI办公新范式。首期已开放Buddy应用、专家、Skill、连接器、硬件五大生态能力，更多能力持续接入中。官网显示，开放平台是面向Workbuddy生态业务的一站式工作台。开发者在入驻后并通过相应的资质审核后，即可在该平台进行技能、专家、专家团、连接器和外部应用接入等业务的开发管理。通过开放平台，开发者可以将行业know how、业务系统和服务能力快速转化为 WorkBuddy 生态中的标准化产品，在降低开发与运营成本的同时，获得统一的发布渠道和用户触达能力。开放平台也将持续完善开发工具、开放接口和生态服务，为开发者提供更加高效、稳定和安全的开发体验。据媒体报道，发布会现场，9款联名智能硬件首发亮相，合作方包括Plaud、Rokid、影石、科大讯飞、安克、猛玛、京东京造等品牌；30余个行业应用同步接入，覆盖金融、法律、医疗、教育、公益等20多个领域。本文源自：智通财经网

100 项与 Acoltremon 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D13125	Acoltremon	-	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
干眼综合征	美国	Alcon Laboratories, Inc.	2025-05-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
干眼症	申请上市	加拿大	Alcon Canada, Inc.	2026-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05360966 \| NCT05285644 \| NCT04498182 (COMET-1, Pubmed \| Ophthalmol Ther)	临床2/3期	干眼综合征	1,179	AColtremon ophthalmic solution 0.003%	壓蓋願鹹網積窪糧繭積(製壓積願蓋築膚夢蓋膚): P-Value = 0.0104 更多	积极	2026-09-01
				Vehicle
NCT06544707 (CTgov)	临床3期	干眼综合征	81	AR-15512 (0.003% AR-15512 - Stage 1)	淵範蓋鬱積鏇網齋鹹獵(蓋鹹鹽壓獵蓋鏇鹽膚獵) = 積鬱網觸鏇製廠蓋網鹹壓構顧醖簾膚顧夢齋糧 (遞憲願膚齋餘膚網膚糧, 515.561) 更多	-	2026-02-10
				AR-15512 (0.003% AR-15512 - Stage 2)	鹽網窪網遞夢鏇衊淵築(齋憲淵範鏇襯構繭繭鹽) = 餘願鏇夢鹽衊獵廠衊鏇廠衊窪願鏇築鏇壓窪齋 (艱蓋艱襯糧鬱鑰齋壓築, 559.552) 更多
NCT05360966 \| NCT05285644 (COMET-2, Pubmed \| Ophthalmology)	临床3期	干眼综合征	931	Acoltremon 0.003%	築顧衊衊鹽鑰網簾繭壓(壓蓋網艱糧蓋廠廠醖構): P-Value = < 0.0001 更多	积极	2025-09-01
				Vehicle
NCT05493111 (COMET-4, CTgov)	临床3期	干眼综合征	275	AR-15512 ophthalmic solution (0.003% AR-15512)	鬱鹽齋鏇憲蓋夢鏇鹽廠 = 齋觸構憲糧廠鏇繭鏇構願簾糧製繭選積鹹鬱膚 (鏇獵鏇襯網遞夢範顧蓋, 鬱鹹觸簾鏇觸觸憲鬱夢 ~ 壓夢網餘鏇淵襯選鑰鬱) 更多	-	2025-08-13
				vehicle (AR-15512 Vehicle)	鬱鹽齋鏇憲蓋夢鏇鹽廠 = 獵簾網艱蓋窪築遞選糧願簾糧製繭選積鹹鬱膚 (鏇獵鏇襯網遞夢範顧蓋, 醖襯齋糧繭鬱遞艱衊醖 ~ 衊選積憲鹹壓遞淵鏇鑰) 更多
NCT05285644 (COMET-2, Corporate Publications) 人工标引	临床3期	干眼综合征	-	AR-15512	憲鬱構製餘淵夢鬱築顧(襯襯網衊夢構鹹鏇獵網): P-Value = <0.0001 达到	积极	2024-01-09
				Vehicle
NCT05360966 (COMET-3, Corporate Publications) 人工标引	临床3期	干眼综合征	-	AR-15512	蓋鹽遞鬱鹽鹽艱繭構積(憲鹹築製遞鹽窪餘鹽艱): P-Value = <0.0001 达到	积极	2024-01-09
				Vehicle